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ABSTRACT 
 Objectives To evaluate the safety and efficacy of pomalidomide (POM) on 
forced vital capacity (FVC), modified Rodnan Skin Score (mRSS), and gastrointestinal 
(GI) symptomatology over 52 weeks of treatment in patients with interstitial lung disease 
due to systemic sclerosis (SSc-ILD). 
 Methods 23 SSc-ILD adult patients diagnosed with SSc1,2 were randomized 1:1 
POM:placebo (PBO). 
 Results: Mean change at Week 52 from baseline in predicted FVC% -5.2 and -
2.8; mRSS -2.7 and -3.7; and UCLA SCTC GIT 2.0 score 0.1 and 0.0, with POM and 
placebo, respectively.  
 Conclusions The study did not meet its Week 52 primary endpoints. POM was 
generally well-tolerated. 
 Funding Celgene Corporation 
 Clinical Trials number NCT01559129 
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 Lung involvement has become the leading cause of deaths directly attributable to 
SSc-ILD.3 Progressive SSc-ILD is associated with inexorable deterioration in lung 
function with associated debility and death, resulting in 5- and 10-year mortality of 30% 
and 50%, respectively.4 
 Pomalidomide (POM) is an IMiDs® compound, structurally similar to thalidomide. 
POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in 
immune-modulation of myeloid and lymphocyte cells. POM exhibits anti-fibrotic activity 
in preclinical models f dermal fibrosis.5 Thalidomide has demonstrated beneficial 
effects in eleven SSc patients treated in an open-label, dose-escalating, 12-week 
study.6 Skin biopsies demonstrated changes in skin fibrosis and an increase in 
epidermal and dermal infiltrating CD8+ T cells with thalidomide treatment. Plasma levels 
of IL-12 and TNF α increased, while IL-5 and IL-10 remained unchanged. These 
changes were associated with beneficial clinical effects, including decreased 
gastroesophageal reflux symptoms, and healing of digital ulcers. Non-clinical studies 
demonstrated that POM has potential anti-fibrotic effects in SSc patients through the 
inhibition of Th2 cytokines and enhanced production of anti-fibrotic Th1 cytokines such 
as IFN-γ, GM-CSF and IL-2.7 These results suggested that POM had potential 
therapeutic benefit as an anti-fibrotic agent to improve pulmonary and dermal fibrosis in 
SSc. 
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METHODS 
 Study design. This phase II, multicenter, randomized, double-blind, parallel-
group study comprised 2 treatment phases, 52 weeks blinded treatment and a two-year 
open-label treatment extension, which was followed by a 4 year long-term follow-up 
phase. The study was conducted in accordance with the general ethical principles 
outlined in the Declaration of Helsinki and following protocol CC-4047-SSC-001 as 
approved by Western IRB, number 20111970. All patients provided their written 
informed consent before starting any study-related procedures. 
 Patients. Eligible patients between 18 and 80 years of age, met the diagnosis of 
limited cutaneous SSc(lSSc) or diffuse cutaneous SSc (dSSc) based on the 2013 
classification criteria for systemic sclerosis, with onset of the first non-Raynaud’s SSc 
symptoms within 7 years prior to screening date. Eligible patients met at least one of the 
following pulmonary-related criteria: (1) FVC readings ≥ 45% and < 70% of predicted 
value at screening and baseline (Visit 2) (2) FVC readings ≥ 70% and ≤ 80% of 
predicted value at screening and baseline (Visit 2) with a documented history of either 
or both (a) a ≥ 5% decrease in FVC in the 24-month period prior to Baseline (based on 
3 or more assessments) or (b) an HRCT fibrosis score > 20%.8 Baseline FVC readings 
within 5% of screening FVC readings were required. Diffusion lung capacity for carbon 
monoxide (DLco) ≥ 35% and ≤ 80% of predicted value was required at screening in 
addition to abnormalities on high resolution computed tomography (HRCT) consistent 
with SSc-related interstitial lung disease, including: honeycombing or reticular changes 
with or without ground glass.9 
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In the 52-week placebo-controlled phase, approximately 88 patients were to be 
randomized 1:1 to placebo or POM 1 mg QD, stratified based on their type of SSc, 
either ([lSSc] or [dSSc]). At week 52, all patients receiving placebo were transitioned to 
POM 1 mg QD in a blinded fashion for up to an additional 2 years; patients receiving 
POM 1 mg QD continued this assigned treatment. Patients were permitted to continue 
other supportive medications at stable doses to treat SSc disease-related symptoms, 
including proton pump inhibitors, angiotensin converting enzyme inhibitors / angiotensin 
receptor blockers, and cough medications. No other Immunosuppressive therapy was 
permitted, except low-dose systemic corticosteroids (≤ 10 mg prednisone or 
equivalent/day). 
 Efficacy assessments. Co-primary efficacy assessments included spirometry 
testing of FVC and forced expiratory volume in 1 second (FEV1), mRSS, and the UCLA 
SCTC GIT V2.0. Secondary efficacy assessments included baseline and transition 
dyspnea indexes (BDI/TDI), and pulse oximetry (SpO2). 
 Safety analysis. At scheduled clinic visits, safety was evaluated based on 
adverse events (AEs), weight, vital signs, physical examination, electrocardiograph 
recordings and clinical laboratory studies. An independentData Monitoring Board was 
implemented for external safety monitoring as an additional safety feature for this study. 
 Statistical analysis. An estimated sample size of 88 patients was needed to 
yield 80% power to detect ≥ 5% difference between POM treatment and placebo, with 
8% of common standard deviation and a 25% discontinuation assumption, using a two-
sample t-test with a 2-sided significance level of 0.1. Efficacy was evaluated based on 
the full analysis set, which consisted of all randomized patients. Safety was evaluated 
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based on the safety population, which consisted of all randomized patients who 
received at least 1 dose of study drug, and safety outcomes were analyzed and 
summarized descriptively. 
RESULTS 
 Patients. A total of 59 patients were screened, 23 were randomized and 22 
received study drug. Eleven patients were randomized in the POM arm and 12 in the 
placebo arm. One patient, who was ineligible for the study, was randomized in the POM 
arm but did not receive study drug. Of these patients, 11 (50.0%) completed 52 weeks, 
with more placebo patients (7 [58.3%]) completing treatment versus (4 [36.4%]) POM 
patients. 
The demographic and disease characteristics of patients at baseline were 
comparable across treatment groups (Table 1).The mean age was 49.8 years (range 31 
to 69 years) in the POM arm and 44.8 years (range 25 to 68 years) in the placebo arm. 
Ninety percent of patients in the POM arm and 83.3% in the placebo arm were female. 
Seventy percent of patients in the POM arm and 83.3% of patients in the placebo arm 
were white. Mean (min, max) body mass index at Scr ening was 26.67 kg/m2 (17.4, 
49.8) and 30.64 kg/m2 (22.0, 40.9) in the POM and placebo arms, respectively. The 
majority of patients had dSSc: eight (80%) and nine (75%) in the POM and placebo 
arms, respectively. 
 Efficacy. Observed changes in all co-primary efficacy endpoints favored 
placebo. In the POM and placebo arms, the mean change at Week 52 from Baseline in 
predicted FVC% was -5.2 and -2.8, for the mRSS was -2.7 and -3.7, and for the UCLA 
SCTC GIT 2.0 instrument total score was 0.1 and 0.0, respectively.10 The only mean 
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decrease (-0.1) from Baseline in the UCLA SCTC GIT 2.0 instrument total score was at 
Week 24 in the POM arm (Table 2). Statistical significance was not achieved for any of 
the three primary endpoints. 
For the secondary efficacy endpoints, improvement in the POM arm was 
reported for the mean change in the UCLA SCTC GIT 2.0 instrument subscale scores of 
Diarrhea (-0.2, -0.3, -0.5, -0.8 at Weeks 12, 24, 76, 156, respectively), and Emotional 
Well-being (-0.4, -0.3, -0.1 at Weeks 12, 24, 52, respectively).11 The change from 
Baseline in dyspnea (as measured by the TDI) regarding Functional Impairment, 
Magnitude of Task, and Magnitude of Effort at Weeks 12, 24 and 52 favored placebo. 
 Safety and tolerability. The safety profile of POM through the placebo-
controlled period and through study termination was comparable. In the 52-week 
placebo-controlled period, adverse events (AEs) were reported by 12 (100.0%) patients 
receiving placebo, and 9 (90.0%) receiving POM 1 mg QD (Table 3). AEs occurring in 
≥10% in either treatment group during this phase included constipation, diarrhea, 
nausea, bronchitis, upper respiratory tract infection, influenza, urinary tract infection, 
ligament sprain, arthralgia, headache, dyspnea, oro-pharyngeal pain, rash, and skin 
ulcer (Table 3). Overall, four POM patients (40%) discontinued due to treatment-
emergent adverse events (TEAEs); one POM patient discontinued due to TEAEs during 
the Open-Label Extension Phase(Table 3). There were four POM patients (40%) with 
serious AE’s (SAEs) compared to one placebo patient (8.3%) during the treatment 
phase; one POM patient had an SAE during the Open-Label Extension Phase (Table 
3). 
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DISCUSSION 
Due to difficulties in recruiting patients for this study related to restrictive inclusion 
and exclusion criteria, the Sponsor prematurely terminated enrollment. Based upon 
interim analysis data, the study did not demonstrate a statistically significant 
improvement in any of the three co-primary efficacy endpoints (changes from Baseline 
in FVC, mRSS or UCLA SCTC GIT 2.0 instrument total score at Weeks 24, or 52 for 
patients who completed blinded treatment. Patients in both the placebo and active 
treatment arms demonstrated disease progression consistent with the natural history of 
SSc-ILD. The study was terminated early due to lack of clinical efficacy of POM over 52 
weeks. At week 52, no trends were noted for the secondary end points over time or by 
treatment group. 
In this study, POM was well tolerated with an AE profile consistent with the 
known safety profile for POM in other diseases. There were no new safety findings from 
this study. Overall TEAEs were comparable across both treatment arms. TEAEs leading 
to discontinuation in the POM arm occurred in four (40%) of the 10 patients. 
Although thalidomide has been shown in an open-label study to have beneficial 
effects in SSC, POM did not improve the clinical measurements in this small, placebo-
controlled SSC-ILD population. There were too few patients to make meaningful 
conclusions. 
CONCLUSIONS 
The current study did not demonstrate efficacy of POM therapy in patients with 
SSC-ILD. POM demonstrated an acceptable safety profile and was generally well-
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tolerated. The safety profile was similar to previous investigations of POM for other 
conditions. 
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Table 1. Baseline demographic and clinical characteristics: full analysis set (N=22) 
Characteristic 
Placebo 
n = 12 
POM 1 mg QD 
n = 10 
Age, mean (SD), years 44.8 (13.8) 49.8 (9.9) 
Female, no. (%) 10 (83.3) 9 (90.0) 
Race, no. (%)   
White 10 (83.3) 7 (70.0) 
Asian 0 (0.0) 2 (20.0) 
Hawaiian Islander 1 (8.3) 0 (0.0) 
Black 0 (0.0) 1 (10.0) 
Missing 1 (8.3) 0 (0.0) 
Weight, mean (SD), kg 80.5 (14.2) 70.8 (25.2) 
BMI, mean (SD), kg/m2 30.64(5.4) 26.67 (9.3) 
Disease type   
Diffuse 9 (75.0) 8 (80.0) 
Limited 3 (25.0) 2 (20.0) 
Calcium Channel Blockers 2 (16.7) 4 (40.0) 
Systemiccorticosteroids 5 (41.7) 7 (70.0) 
Drugs for Acid Related Disorders§ 4 (33.3) 7 (70.0) 




esomeprazole, omeprazole, pantaprazole, or sucralfate. 
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Table 2. Primary end points Weeks 24 and 52: full analysis set (N=22) 
 
Placebo Pomalidomide 1 mg QD 
(N=12) (N=10) 










Predicted FVC (%) Baseline
a
 n - 12 - - 10 - 
Mean (±SD) - 60.9 (8.6) - - 53.7 (7.3) - 
Min, Max - 47, 77 - - 45, 67 - 
Week 24 n
b
 10 10 10 8 8 8 
Mean (±SD) 63.2 (7.3) 61.9 (8.6) -1.3 (3.3) 53.6 (8.1) 55.9 (13.6) 2.3 (12.6) 





 11 11 11 8 8 8 
Mean (±SD) 60.7 (9.0) 57.9 (10.0) -2.8 (4.0) 53.2 (8.2) 48 (8.6) -5.2 (5.3) 
Min, Max 47, 77 41, 77 -8, 5 45, 67 40, 61 -15, 4 
mRSS Baseline n - 11 - - 10 - 
Mean (±SD) - 20.5 (10.0) - - 17.1 (9.4) - 
Min, Max - 2, 32 - - 4, 30 - 
Week 24 n
a
 10 10 10 8 8 8 
Mean (±SD) 19.6 (10.1) 16 (9.8) -3.6 (5.7) 15 (9.0) 13 (10.5) -2 (3.4) 
Min, Max 2, 32 3, 28 -13, 3 4, 27 2, 29 -6, 3 
Week 52 n
a
 11 11 11 10 10 10 
Mean (±SD) 20.5 (10.0) 16.7 (10.9) -3.7 (7.0) 17.1 (9.4) 14.4 (10.1) -2.7 (5.7) 
Min, Max 2, 32 1, 31 -15, 7 4, 30 2, 30 -9, 10 
UCLA SCTC GIT 2.0 Baseline n - 12 - - 10 - 
Mean (±SD) - 0.2 (0.18) - - 0.5 (0.29) - 
Min, Max - 0, 1 - - 0, 1 - 
Week 24 n
a
 10 10 10 8 8 8 
Mean (±SD) 0.2 (0.19) 0.3 (0.32) 0.1 (0.23) 0.5 (0.28) 0.4 (0.24) -0.1 (0.2) 
Min, Max 0, 1 0, 1 0, 0 0, 1 0, 1 0, 0 
Week 52 n
a
 12 12 12 10 10 10 
Mean (±SD) 0.2 (0.18) 0.3 (0.2) 0 (0.18) 0.5 (0.29) 0.5 (0.39) 0.1 (0.29) 
Min, Max 0, 1 0, 1 0, 0 0, 1 0, 1 0, 0 
a
FVC Baseline: average of Screening and Baseline. FVC Week 52: average of Week 48 and Week 52. 
b
 At a post-baseline time point for Baseline and Change from Baseline column, n = number of patients with a 
Baseline value and a post-baseline value at the time point. None of the primary end points achieved statistical 
significance. As a result, P values are not provided. 
FVC = forced vital capacity; mRSS = modified Rodnan skin score; QD = once daily; SD = standard deviation; UCLA 
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Weeks 0 to 52* 
Open-Label/ 
study termination§ 
Patients, n (%) 
Placebo 
n= 12 
POM 1 mg QD 
n= 10 
Placebo* 
n = 6 
POM 1 mg QD 
n= 2 
AE summary 
≥1 AE 12 (100.0) 9 (90.0) 5 (83.3) 2 (100.0) 
≥1 serious AE 1 (8.3) 4 (40.0) 0 (0.0) 1 (50.0) 
≥1 severe AE 1 (8.3) 4 (40.0) 0 (0.0) 0 (0.0) 
AEs leading to drug 
withdrawal 
discontinuation 
0 (0.0) 4 (40.0) 0 (0.0) 1 (50.0) 
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
AEs reported by ≥10% of patients in any treatment group, n (%) 
Constipation 1 (8.3) 3 (30.0) 0 (0.0) 0 (0.0) 
Diarrhea 3 (25.0) 1 (10.0) 0 (0.0) 0 (0.0) 
Nausea 2 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 
Bronchitis 0 (0.0) 2 (20.0) 0 (0.0) 0 (0.0) 
Upper respiratory tract 
infection 
3 (25.0) 1 (10.0) 0 (0.0) 0 (0.0) 
Influenza 2 (16.7) 0 (0.0) 2 (33.3) 0 (0.0) 
Urinary tract infection 2 (16.7) 0 (0.0) 2 (33.3) 0 (0.0) 
Ligament sprain 0 (0.0) 2 (20.0) 0 (0.0) 0 (0.0) 
Arthralgia 4 (33.3) 4 (40.0) 0 (0.0) 0 (0.0) 
Headache 3 (25.0) 1 (10.0) 0 (0.0) 0 (0.0) 
Dyspnea 2 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 
Oropharyngeal pain 2 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 
Productive cough 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 
Rash 1 (8.3) 2 (20.0) 0 (0.0) 0 (0.0) 
Skin ulcer 2 (16.7) 0 (0.0) 2 (33.3) 0 (0.0) 
Serious AEs  
Infections and 
infestations 
    
Pneumonia 1 (8.3) 1 (10.0) 0 (0.0) 1 (50.0) 
Upper respiratory 
tract infection 
0 (0.0) 1 (10.0)   
Sepsis 1 (8.3) 0 (0.0) 1 (16.7) 0 (0.0) 
Renal and urinary 
disorders 
    
Renal failure 0 (0.0) 1 (10.0) 1 (16.7) 0 (0.0) 
Respiratory, thoracic, 
mediastinal disorders 
    
Pulmonary 
embolism 
0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 




0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 
Chronic 
respiratory failure 
0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 
Pulmonary 
hypertension 
0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 
AEs Leading to Discontinuation 
C-reactive protein 
increased 
0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 
Renal failure 0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 
Pulmonary 
embolism 
0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 
Toxic skin 
eruption 
0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 
AE = adverse event; POM = pomalidomide; QD = once daily 
* Placebo-controlled period includes all data through week 52, and for the open-label extension data is 
for patients initially assigned to placebo who were re-randomized to active treatment appear in the 
placebo column. 
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